JCHOR
Journal of Current Hematology & Oncology Research

The Journal of Current Hematology & Oncology Research regularly publishes internationally qualified research in hematology and oncology within the current scholarly knowledge.

ISSN: Active
eISSN: 2980-0854
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Original Article
Safety profile and predictors of procedural complications in automated erythrocytapheresis for sickle cell disease: a single-center retrospective cohort study
Abstract
Aims: Automated erythrocytapheresis (red cell exchange; RCE) is an established therapeutic modality in sickle cell disease (SCD), yet procedural complication data from Turkey and the Eastern Mediterranean region remain limited. This study evaluated the safety profile of RCE in adult SCD patients at a single tertiary center and identified clinical and procedural predictors of adverse events.
Methods: We conducted a retrospective cohort study of all automated RCE procedures performed in adult patients (?18 years) with SCD between January 2015 and December 2020. Adverse events were graded according to the World Apheresis Association (WAA) classification (Grades 1–4). Procedures with and without complications were compared using the Mann–Whitney U test for continuous variables and Fisher’s exact or chi-square tests for categorical variables.
Results: A total of 274 procedures in 83 patients were analyzed. The overall complication rate was 12.4% (n=34): Grade 1 in 4.4%, Grade 2 in 5.8%, and Grade 3 in 2.2%; no Grade 4 events were observed. Vascular and mechanical dysfunction accounted for 67.6% of complications. Complication rates declined from 31.2% in 2015 to 5.5% in 2018, with no severe events after 2016. Higher pre-procedure hemoglobin (9.4 vs. 8.9 g/dL; p=0.021) and hematocrit (27.0% vs. 25.9%; p=0.022) were significantly associated with complication occurrence. MCS® procedures had a substantially higher complication rate (42.9% vs. 10.8%; p=0.003) and severe event rate (28.6% vs. 0.8%; OR=51.4; p=0.0001) versus the Spectra Optia® system. Indication and hydroxyurea use were not significantly associated with outcomes.
Conclusion: Automated RCE is a safe procedure in adult SCD patients with a low rate of severe adverse events. Higher pre-procedure hemoglobin and hematocrit and use of the MCS® device were associated with increased complication risk. The marked temporal decline in complication rates reflects institutional learning and device transition to the Spectra Optia® platform.

Keywords : hemoglobin S; vaso-occlusive crisis; transfusion medicine; adverse events; apheresis device; fetal hemoglobin

Download Article


1. Piel FB, Patil AP, Howes RE, et al. Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. Lancet. 2013;381(9861):142-151. doi:10.1016/s0140-6736(12)61229-x
2. Ware RE, de Montalembert M, Tshilolo L, Abboud MR. Sickle cell disease. Lancet. 2017;390(10091):311-323. doi:10.1016/s0140-6736(17)30193-9
3. Cürük MA, Zeren F, Genç A, Ozavci-Aygün S, Kilinç Y, Aksoy K. Prenatal diagnosis of sickle cell anemia and beta-thalassemia in southern Turkey. Hemoglobin. 2008;32(6):525-530. doi:10.1080/03630260802508269
4. Steinberg MH. Pathophysiologically based drug treatment of sickle cell disease. Trends Pharmacol Sci. 2006;27(4):204-210. doi:10.1016/j.tips.2006.02.007
5. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med. 1994; 330(23):1639-1644. doi:10.1056/nejm199406093302303
6. Swerdlow PS. Red cell exchange in sickle cell disease. Hematology Am Soc Hematol Educ Program. 2006:48-53. doi:10.1182/asheducation-2006.1.48
7. Kelly S. Logistics, risks, and benefits of automated red blood cell exchange for patients with sickle cell disease. Hematology Am Soc Hematol Educ Program. 2023;2023(1):646-652. doi:10.1182/hematology.2023000498
8. Padmanabhan A, Connelly-Smith L, Aqui N, et al. Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the writing committee of the American Society for Apheresis: the eighth special issue. J Clin Apher. 2019;34(3):171-354. doi:10.1002/jca.21705
9. Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med. 1998;339(1):5-11. doi:10.1056/nejm199807023390102
10. Adams RJ, Brambilla D. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med. 2005;353(26):2769-2778. doi:10.1056/NEJMoa050460
11. Mörtzell Henriksson M, Newman E, Witt V, et al. Adverse events in apheresis: an update of the WAA registry data. Transfus Apher Sci. 2016;54(1):2-15. doi:10.1016/j.transci.2016.01.003
12. Vrielink H, Le Poole K, Stegmayr B, et al. The world apheresis association registry, 2023 update. Transfus Apher Sci. 2023;62(6):103831. doi:10.1016/j.transci.2023.103831
13. Stegmayr BG, Ivanovich P, Korach JM, Rock G, Norda R, Ramlow W. World apheresis association--world apheresis registry. Transfus Apher Sci. 2005;32(2):205-207. doi:10.1016/j.transci.2004.10.015
14. Michot JM, Driss F, Guitton C, et al. Immunohematologic tolerance of chronic transfusion exchanges with erythrocytapheresis in sickle cell disease. Transfusion. 2015;55(2):357-363. doi:10.1111/trf.12875
15. Karacaoglu PK, Asma S, Korur A, et al. East Mediterranean region sickle cell disease mortality trial: retrospective multicenter cohort analysis of 735 patients. Ann Hematol. 2016;95(6):993-1000. doi:10.1007/s00277-016-2655-5
16. Szczepiorkowski ZM, Winters JL, Bandarenko N, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher. 2010;25(3):83-177. doi:10.1002/jca.20240
17. Habibi A, Mekontso-Dessap A, Guillaud C, et al. Delayed hemolytic transfusion reaction in adult sickle-cell disease: presentations, outcomes, and treatments of 99 referral center episodes. Am J Hematol. 2016;91(10):989-994. doi:10.1002/ajh.24460
18. Chou ST, Alsawas M, Fasano RM, et al. American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support. Blood Adv. 2020;4(2):327-355. doi:10.1182/bloodadvances.2019001143
19. Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA. 2014;312(10):1033-1048. doi:10.1001/jama.2014.10517
20. DeBaun MR, Jordan LC, King AA, et al. American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults. Blood Adv. 2020;4(8):1554-1588. doi:10.1182/bloodadvances.2019001142
21. Baskurt OK, Meiselman HJ. Blood rheology and hemodynamics. Semin Thromb Hemost. 2003;29(5):435-450. doi:10.1055/s-2003-44551
22. Estcourt LJ, Kohli R, Hopewell S, Trivella M, Wang WC. Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. Cochrane Database Syst Rev. 2020;7(7):Cd003146. doi:10.1002/14651858.CD003146.pub4
23. Hequet O, Poutrel S, Connes P, et al. Automatic depletion with Spectra Optia allows a safe 16% reduction of red blood cell pack consumption in exchanged sickle cell anemia patients. Transfusion. 2019;59(5):1692-1697. doi:10.1111/trf.15188
24. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the multicenter study of hydroxyurea in sickle cell anemia. N Engl J Med. 1995;332(20):1317-1322. doi:10.1056/nejm199505183322001
Article available in :
Volume 4, Issue 3, 2026
Page : 110-115
https://doi.org/10.51271/JCHOR-0092
Article Information
Received : 05 May 2026
Accepted : 13 Tem 2026
Published : 08 Ağu 2026
Corresponding Author :

Sinan Mersin: Department of Hematology, Faculty of Medicine, Mersin University, Mersin, Turkiye

[email protected]
Citation : Mersin S, Aytan P, Koyuncu MB, et al. Safety profile and predictors of procedural complications in automated erythrocytapheresis for sickle cell disease: a single-center retrospective cohort study. J Curr Hematol Oncol Res. 2026;4(3):110-115. doi:10.51271/JCHOR-0092

Read: 8
Download : 5
Cited: 0
_Footer